Amlodipine Diabetic Hypertension Efficacy Response Trial


Last updated date


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
30-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Documented evidence of Type 2 diabetes as defined by the ADA guidelines and documented evidence of Hypertension (various SBP/DBP ranges).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- A previous history or intolerance or hypersensitivity to calcium channel blockers,
ARBs or ACE inhibitors.


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

HypertensionAmlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients NCT01200407
  1. San Fernando City, La Union
  2. Taclobo, Dumaguete City, Negros Oriental
  3. Albay,
  4. Angono,
  5. Baguio City,
  6. Baguio,
  7. Bulacan,
  8. Calamba,
  9. Cavite,
  10. Cebu City,
  11. Cebu,
  12. Dagupan,
  13. Davao City,
  14. Davao,
  15. Eastwood,
  16. Iloilo City,
  17. Iloilo,
  18. Isabela,
  19. Kalibo Aklan,
  20. Laguna,
  21. Laoag,
  22. Lingayen, Pangasinan,
  23. Makati City,
  24. Makati City,
  25. Makati,
  26. Mandaluyong,
  27. Manila,
  28. Manila,
  29. Manila,
  30. Manila,
  31. Manila,
  32. Manila,
  33. Marikina City,
  34. Marikina,
  35. Metro Manila,
  36. Muntinlupa,
  37. Nueva Vizcaya,
  38. Olongapo,
  39. Pampanga,
  40. Paranaque,
  41. Parañaque,
  42. Pasay,
  43. Pasig City,
  44. Pasig Ciy,
  45. Pasig,
  46. Pasig,
  47. Puerto Princesa,
  48. Quezon City,
  49. Quezon CIty,
  50. Rizal,
  51. San Juan,
  52. Tacloban,
  53. Taguig,
  54. Tarlac,
  55. Tugegarao,
  56. Tuguegarao City,
  57. Tuguegarao City,
18 Years+
HypertensionA Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents NCT00389519
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Beverly Hills, California
  4. Los Angeles, California
  5. Orange, California
  6. Cocoa Beach, Florida
  7. Lakeland, Florida
  8. Atlanta, Georgia
  9. Augusta, Georgia
  10. Honolulu, Hawaii
  11. Park Ridge, Illinois
  12. Tinley Park, Illinois
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bridgeton, Missouri
  16. Las Vegas, Nevada
  17. Las Vegas, Nevada
  18. Toms River, New Jersey
  19. Syracuse, New York
  20. Williamsville, New York
  21. Cary, North Carolina
  22. Chapel Hill, North Carolina
  23. Durham, North Carolina
  24. Sylva, North Carolina
  25. Cincinnati, Ohio
  26. Columbus, Ohio
  27. Norman, Oklahoma
  28. Tulsa, Oklahoma
  29. Portland, Oregon
  30. Portland, Oregon
  31. Philadelphia, Pennsylvania
  32. Kingsport, Tennessee
  33. Memphis, Tennessee
  34. Beaumont, Texas
  35. Houston, Texas
  36. Salt Lake City, Utah
  37. Charlottesville, Virginia
  38. Midlothian, Virginia
  39. Norfolk, Virginia
  40. Buenos Aires,
  41. Buenos Aires,
  42. Buenos Aires,
  43. Buenos Aires,
  44. San Juan,
  45. Tucomán,
  46. Santiago,
  47. Santiago,
  48. Santiago,
  49. Vina del Mar,
  50. Barranquilla,
  51. Bogotá,
  52. Bogotá,
  53. Bogotá,
  54. Medellin,
  55. Medellin,
  56. Medellín,
  57. Ahmedabad,
  58. Ahmedabad,
  59. Bangalore,
  60. Chennai,
  61. Delhi,
  62. Delhi,
  63. Delhi,
  64. Hyderabaad,
  65. Hyderabaad,
  66. Ludhiana,
  67. Mumbai,
  68. Pune,
  69. Trivandrum,
  70. Gdansk,
  71. Katowice,
  72. Lodz,
  73. Lodz,
  74. Poznan,
  75. Szczecin,
  76. Szczecin,
  77. Torun,
  78. Warszawa,
  79. Wroclaw,
  80. Benoni,
  81. Johannesburg,
  82. Port Elizabeth,
  83. Potchefstroom,
  84. Pretoria,
  85. Pretoria,
  86. Pretoria,
  87. Pretoria,
  88. Sandton,
  89. Istanbul,
  90. Istanbul,
  91. Izmir,
  92. Samsun,
  93. Dnepropetrovsk,
  94. Kharkov,
  95. Kiev,
  96. Kyiv,
  97. Lviv,
  98. Odessa,
  99. Simferopol,
  100. Uzhorod,
  101. Vinnitsa,
6 Years+
HypertensionA Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient NCT00415623
  1. Kasuya-gun, Fujuoka
  2. Chikushino, Fukuoka
  3. Kitakyushu, Fukuoka
  4. Koga, Fukuoka
  5. Sapporo, Hokkaidou
  6. Sapporo, Hokkaido
  7. Yokohama, Kanagawa
  8. Iruma, Saitama
  9. Koshigaya, Saitama
  10. Adachi-ku, Tokyo
  11. Edogawa-ku, Tokyo
  12. Meguro-ku, Tokyo
  13. Setagaya-ku, Tokyo
  14. Sumida, Tokyo
  15. Fukuoka,
20 Years+
HypertensionTreatment of Pediatric Hypertension With Altace Trial NCT00044265
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Augusta, Georgia
  6. Honolulu, Hawaii
  7. Park Ridge, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Baltimore, Maryland
  11. Detroit, Michigan
  12. Kansas City, Missouri
  13. St. Louis, Missouri
  14. Bronx, New York
  15. Great Neck, New York
  16. Cincinnati, Ohio
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Columbus, Ohio
  20. Portland, Oregon
  21. Hershey, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Philadelphia, Pennsylvania
  24. Pittsburgh, Pennsylvania
  25. Memphis, Tennessee
  26. Nashville, Tennessee
  27. Houston, Texas
  28. Houston, Texas
  29. Charlottesville, Virginia
  30. Madison, Wisconsin
6 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Amlodipine Diabetic Hypertension Efficacy Response Trial
Official Title  ICMJE A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects
Brief Summary To evaluate the percentage of subjects that reach the diabetic hypertensive blood pressure goal of <130/80 with amlodipine versus placebo in subjects initially treated with quinapril or losartan.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE Drug: Amlodipine
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 6, 2009)
Original Enrollment  ICMJE
 (submitted: September 8, 2005)
Actual Study Completion Date  ICMJE August 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Documented evidence of Type 2 diabetes as defined by the ADA guidelines and documented evidence of Hypertension (various SBP/DBP ranges).

Exclusion Criteria:

  • A previous history or intolerance or hypersensitivity to calcium channel blockers, ARBs or ACE inhibitors.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 30 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00159692
Other Study ID Numbers  ICMJE A0531063
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP